In the (hopefully not-too-distant) future, once Nagalase testing and GcMAF are available, all people at risk of cancer—i.e., everyone over the age of 40—will get an annual Nagalase test along with their other routine blood tests (complete blood count, comprehensive metabolic panel, vitamin D, lipid panel, etc.).
Nagalase could become our standard marker for early cancer detection. Those with an elevated Nagalase (after ruling out a viral cause) will be treated “presumptively” (i.e., we know it’s in there even though we can’t actually see it) with GcMAF and/or other alternative cancer therapies.
Follow up Nagalase testing will document the patient’s progress. Once the cancer is gone, as documented by a return of Nagalase to baseline, subsequent testing will provide an early warning if cancer starts growing again.
Immune-Activator 